BioMarin Voxzogo Expansion in Hypochondroplasia

BioMarin reported positive Phase 3 data for Voxzogo in hypochondroplasia, exceeding efficacy expectations and paving the way for a 3Q 2026 sNDA submission.

Key Takeaways

• 1.BioMarin reported positive Phase 3 topline data for Voxzogo in hypochondroplasia, meeting the primary endpoint of 52-week change in annualized growth velocity (2.33cm/yr).
• 2.Management plans to submit a supplemental New Drug Application (sNDA) in 3Q 2026, with potential commercial launch in 2027.
• 3.The global addressable population for hypochondroplasia is estimated at 14,000, with peak sales modeled at approximately $300 million.

Table of Contents

• BioMarin Pharmaceutical Inc. (BMRN): Positive topline hypochondroplasia data unlocks a Voxzogo expansion opportunity
• Valuation and risks
• Disclosure Appendix
• Reg AC
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial